Non-invasive biomarkers, FIB-4 and APRI index, as predictors for prognosis of hepatocellular carcinoma patients after curative hepatectomy

Yun, Sang Oh; KIM, Jong Man; Rhu, Jinsoo; Choi, Gyu‐Seong; Joh, Jae‐Won

doi:10.14701/ahbps.2022s1.op-5-7

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We looked forward to verifying that differences in GP73 expression might also correlate with the liver function status of the enrollees, so the MELD and Child‐Pugh score, which reflects the function of liver reserve, was calculated based on the above data. AAR = AST/ALT; ALBI = 0.66 × log 10 bilirubin (µmol/L)‐0.085 × albumim (g/L) 17 . Serum GP73 level was quantitatively measured by chemiluminescence immunoassay kits.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Liu,

Ma,

Chen

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatic venous pressure gradient (HVPG) is the gold standard for evaluating clinically significant portal hypertension (CSPH). However, reliable noninvasive methods are limited. Our study aims to investigate the diagnostic value of serum Golgi protein 73 (GP73) for CSPH in patients with compensated cirrhosis. The study enrolled 262 consecutive patients with compensated cirrhosis from three centers in China from February 2021 to September 2023, who underwent both serum GP73 tests and HVPG measurements. CSPH was defined as HVPG ≥ 10 mmHg. Diagnostic accuracy was evaluated using the areas under the receiver operating characteristic curve (AUC). The prevalence of CSPH was 56.9% (n = 149). There were significant differences between the CSPH and non‐CSPH groups in the median serum GP73 level (126.8 vs. 73.1 ng/mL, p < 0.001). GP73 level showed a significant positive linear correlation with HVPG (r = 0.459, p < 0.001). The AUC for the diagnosis of CSPH using serum GP73 alone was 0.75 (95% confidence interval [CI] 0.68–0.81). Multivariate logistic regression analysis determined that the levels of GP73, platelets and international normalized ratio were independently associated with CSPH. The combination of these three markers was termed “IP73” score with an AUC value of 0.85 (95% CI 0.80–0.89) for CSPH. Using 0 as a cut‐off value, the specificity and sensitivity of IP73 score were 77.9% and 81.9%, respectively. The IP73 score offers a novel, simple and noninvasive method of assessing CSPH in patients with compensated cirrhosis. A cut‐off value of the IP73 score at 0 can distinguish patients with or without CSPH.

show abstract

Section: Methodsmentioning

confidence: 99%

“…AAR = AST/ALT; ALBI = 0.66 × log 10 bilirubin (µmol/L)-0.085 × albumim (g/L). 17 Serum GP73 level was quantitatively measured by chemiluminescence immunoassay kits. The operation procedure is carried out in strict accordance with the manufacturer's protocol.…”

Section: Clinical and Laboratory Evaluationsmentioning

confidence: 99%

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Liu,

Ma,

Chen

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The surveillance protocol post-surgery at our center has been previously described. 12,13 Abdominal computed tomography (CT) was conducted every 3 months or when recurrence was suspected. Magnetic resonance imaging and/or positron emission tomography scans were used if CT could not definitively detect recurrence.…”

Section: Surveillance After Surgical Resectionmentioning

confidence: 99%

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

Lim,

Kim,

Rhu

et al. 2024

JLC

View full text Add to dashboard Cite

Background/Aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC.Methods: The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT).Results: Fifty-eight patients (90.6%) had Vp3 PVTT, whereas the remaining six patients exhibited Vp4 PVTT. The median tumor size measured 8 cm, with approximately 36% of patients presented with multiple tumors. Fifty-four patients (84.4%) underwent open LR, whereas 10 patients underwent laparoscopic LR. In the Vp4 cases, combined LR and tumor thrombectomy were performed. The 3-year cumulative disease-free survival rate was 42.8% for the Vp3 group and 22.2% for the Vp4 group. The overall survival (OS) rate at 3 years was 47.9% for the Vp3 group and 60.0% for the Vp4 group. Intrahepatic metastasis has been identified as an important contributor to HCC recurrence. High hemoglobin levels are associated with high mortality.Conclusion: LR is a safe and effective treatment modality for selected patients with Vp3 or Vp4 HCC PVTT. This suggests that LR is a viable option for these patients, with favorable outcomes in terms of OS.

show abstract

Non-invasive biomarkers, FIB-4 and APRI index, as predictors for prognosis of hepatocellular carcinoma patients after curative hepatectomy

Cited by 2 publications

References 0 publications

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

Contact Info

Product

Resources

About